Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 36 NSCLC 9 Meningeal Carcinomatosis 5 Adenocarcinoma of Lung 5 Lung Neoplasms 4 Brain Neoplasms 4 Respiratory Tract Neoplasms 1 Pleural Effusion, Malignant 1 Non Small Cell Lung Cancer NSCLC 1 Neoplasm, Residual 1 Multiple Primary Lung Cancers 1 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer 1 EGF-R Positive Non-Small Cell Lung Cancer 1 Carcinoma 1 Bronchial Neoplasms 1 Advanced Non-small Cell Lung Cancer 1 Advanced NSCLC Patients With T790M 1 Advanced NSCLC 1 Advanced Lung Cancer 1 Adenocarcinoma 1

Interventions

Cisplatin 55 Carboplatin 50 pembrolizumab 42 Paclitaxel 42 Gemcitabine 28 Pemetrexed 23 Radiotherapy 21 Magnetic Resonance Spectroscopy 20 Radiotherapy, Intensity-Modulated 18 Cetuximab 18 Docetaxel 17 Specimen Handling 16 Nivolumab 16 Fluorouracil 16 Cyclophosphamide 14 durvalumab 13 Bevacizumab 13 Sorafenib 12 Radiation 11 130-nm albumin-bound paclitaxel 11 Sunitinib 10 Platinum 10 1,2-diaminocyclohexaneplatinum II citrate 10 osimertinib 9 Oxaliplatin 8 Irinotecan 8 Ipilimumab 8 Everolimus 8 Drug Therapy 8 Capecitabine 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × aflutinib × Clear all

NCT04401059 2023-12-27

SELECT-2

Hangzhou Normal University

Phase 4 Unknown

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡